Drug profile · INN
antazoline phosphate
VASOCON-A
antazoline phosphate (VASOCON-A) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — antazoline phosphate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
antazoline phosphate (VASOCON-A) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is antazoline phosphate?
antazoline phosphate (VASOCON-A) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for antazoline phosphate?
VASOCON-A is a marketed brand name for antazoline phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of antazoline phosphate?
antazoline phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.